依普利酮在北京购买的到吗？

It is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the State Food and Drug Administration in 2002. It has extremely low affinity for androgen and progesterone receptors and has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative to spironolactone.

For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction. 

So, can eplerenone be purchased in Beijing?

Purchasing channels for eplerenone in Beijing: It is understood that eplerenone has not yet been officially launched in China, and patients can purchase the foreign version of eplerenone!

When it comes to buying medicines, the first thing that comes to mind is the price. According to Medical Travel, we learned that eplerenone 50mg × 100 tablets from India's Lupine Pharmaceuticals costs about $500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.

If you want to buy high-quality and low-cost eplerenone, you can go abroad to buy it yourself. For patients who are inconvenient to go abroad, the most reliable way is to buy it through domestic regular overseas medical service institutions, which will sign a guarantee contract for you to guarantee 100% authenticity!

A new generation of selective aldosterone antagonists (eplerenone) was developed by Pfizer/Pharmacia, and eplerenone is the first aldosterone receptor blocker approved for this indication. The FDA's approval was based on the results of the EPHESUS (Eplerenone Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial. In patients with heart failure after myocardial infarction, eplerenone plus standard care reduced mortality by 15% compared with placebo and standard care (ACE inhibitors and beta-blockers).